Poolbeg Pharma A.I. Unlocking the power of unique human challenge trial data

Poolbeg Pharma A.I. Unlocking the power of unique human challenge trial data

Poolbeg Pharma (LON:POLB) Chief Executive Officer Jeremy Skillington talks us through the Poolbeg September 2023 company presentation.

Poolbeg Pharma (LON:POLB, OTCQB: POLBF), is a clinical-stage biopharmaceutical company focusing on infectious and other prevalent diseases with a high unmet medical need.

Share on:
Find more news, interviews, share price & company profile here for:
Poolbeg Pharma and HOOKIPA Pharma propose a new collaboration with Gilead Sciences set to invest up to $8.7495 million, pending further negotiations.
Los Consejos de Poolbeg Pharma y HOOKIPA Pharma anuncian el respaldo de Gilead para una posible oferta y la actualización de su recaudación de fondos.
Poolbeg Pharma and HOOKIPA Pharma confirm Gilead Sciences' support for participation in a $30 million+ private placement fundraise amid potential merger talks.
HOOKIPA Pharma and Poolbeg Pharma are exploring a potential all-share acquisition, aiming to create a powerful Nasdaq-listed biopharmaceutical entity.
Poolbeg Pharma unveils promising POLB 001 data at ASH Meeting, highlighting its potential as a CRS preventative therapy in cancer immunotherapies.
Poolbeg Pharma secures US patent approval for POLB 001, enhancing its IP portfolio and advancing treatments for severe influenza and cytokine storms.

Search

Search